Are you interested in learning about our current study on developing personalized, immune-based therapy to trigger patients’ own immune responses against tumors?
Watch Dr. Peter Bauer, MD, Chief Scientific Officer at CENTOGENE, as he discusses ‘PICoP global’ – our recently launched two-year global study that may have a considerable impact on cancer immunotherapy and individualized treatment for patients via peptide-based immunization for Colon- and Pancreas-Carcinoma.
• Colon and pancreas cancer in the developing countries
• Cancer immune therapy
• Neoepitopes as targets for patient-specific immune therapy
• Molecular approaches to identify neoepitopes
Prof. Peter Bauer, M.D., serves as CENTOGENE’s Chief Genomic Officer, where he combines […]